Microdosing semaglutide — using sub-therapeutic doses of the GLP-1 receptor agonist for metabolic benefits rather than weight loss — is one of the most discussed yet least documented practices in precision medicine today.
I have been doing it for six months. My BMI is 20.8. I am not obese. This article explains why — and what the science actually says about microdosing semaglutide in people who do not need to lose weight.
What Is Microdosing Semaglutide?
Standard therapeutic doses of semaglutide for weight loss range from 0.5 mg to 2.4 mg weekly. These doses are calibrated to produce significant appetite suppression and weight reduction in people with obesity.
Microdosing refers to sub-therapeutic use — typically 0.125 mg to 0.25 mg weekly — where the goal is not weight loss but metabolic modulation. At these doses, the drug engages GLP-1 receptors throughout the body without driving the aggressive appetite suppression that characterizes full therapeutic dosing.
This is an off-label, emerging practice. There is no clinical guideline supporting it. I am not recommending it. I am explaining what it is and why it is generating serious scientific interest.
Why Would a Normal-Weight Person Use Semaglutide?
The short answer: because GLP-1 receptors are not only in your gut.
GLP-1 receptors are expressed in cardiac tissue, the brain, the liver, the pancreas, and the vasculature. When semaglutide activates these receptors, it does not just suppress appetite. It also:
- Supports pancreatic beta-cell function and insulin secretion
- Reduces hepatic fat accumulation independent of weight loss
- Decreases systemic inflammation (hs-CRP, IL-6 pathway)
- Provides direct cardioprotective effects in cardiac tissue
- Modulates brain GLP-1R networks involved in metabolic regulation
The LEADER and SUSTAIN-6 cardiovascular outcome trials demonstrated meaningful reductions in major adverse cardiovascular events with GLP-1 agonists. Post-hoc analyses of these trials consistently show that cardiovascular protection was not proportional to weight lost — suggesting the molecule has weight-independent mechanisms.
A 2021 pharmacokinetic analysis by Overgaard et al. in Cell Reports Medicine compared oral versus subcutaneous semaglutide at identical plasma concentrations. At matched drug levels, both routes produced statistically identical outcomes across all endpoints — confirming that systemic drug exposure, not route or local GI effects, drives the metabolic and cardiovascular benefits.
In other words: for someone with the right risk profile, the beneficial biology of semaglutide does not require obesity to be relevant.
My Risk Profile — Why I Made This Decision
Family History and Coronary Findings
My father had his first myocardial infarction at 41. He died of a second one at 54. Three years ago, a coronary CT angiography found 50% atherosclerotic plaque in my left main coronary artery. I am 56. Normal weight. Metabolically “normal” on standard panels. And I have documented coronary disease and a powerful family history.
For several years, I used low-dose aspirin as secondary prevention — on my cardiologist’s recommendation. Twelve months ago, I stopped. The reason was Beta Thalassemia Minor combined with gastrointestinal bleeding. This hematological profile made continued aspirin use a risk I was no longer willing to accept.
Stopping aspirin created a gap. That gap, combined with my genetic findings, shaped my decision.
Genetic Profile and GLP-1 Pharmacogenomics
Over the past year I had a comprehensive pharmacogenomic panel performed — the same analysis we use at BariatrikLab Longevity Clinic for patient evaluation. The relevant findings:
TCF7L2 rs7903146: CT heterozygous. One of the strongest genetic risk factors for type 2 diabetes. This variant impairs pancreatic beta-cell insulin secretion capacity. My HbA1c is currently 5.2% — compensated — but the genetic substrate for future metabolic drift is present. GLP-1’s incretin effect directly supports the pathway this variant compromises.
PNPLA3 rs738409: CG heterozygous. Moderate genetic loading toward non-alcoholic fatty liver disease, independent of body weight. Family history of hepatic disease confirms this signal. GLP-1 and GIP agonists reduce liver fat in PNPLA3 variant carriers through mechanisms independent of weight change.
GIPR rs1800437: GG (wild-type). A 2026 GWAS study in Nature (27,885 participants) found that carriers of the variant allele had 83% higher nausea risk with tirzepatide specifically. My GG genotype indicates favorable GI tolerability for both semaglutide and tirzepatide — relevant given my history of GI sensitivity.
APOE ε3/ε3. Neutral cardiovascular haplotype. No APOE4-driven amplification of cardiovascular risk. This supports full utilization of GLP-1’s cardioprotective mechanisms.
The genetic summary: low side effect risk, meaningful metabolic and hepatoprotective benefit potential, direct relevance to my known cardiovascular vulnerability.
Six Months of Microdosing Semaglutide — What the Lab Shows
My laboratory values were drawn in March 2026, approximately six months into 0.125 mg semaglutide weekly. These are post-intervention values, not baseline. I do not have a clean before-after comparison — I designed this as a clinical decision, not a controlled experiment.
Metabolic panel: Fasting glucose 87 mg/dL, HbA1c 5.2%, HOMA-IR 1.20 — no insulin resistance.
Lipids: Total cholesterol 119 mg/dL (on rosuvastatin 5 mg), triglycerides 38 mg/dL, LDL 59 mg/dL, HDL 55 mg/dL (below optimal — a persistent signal worth monitoring), total/HDL ratio 2.2.
Inflammation: hs-CRP 0.30 mg/L — low cardiovascular risk zone.
Liver enzymes: ALT 29, GGT 9, AST 37 — all within range.
What I notice clinically: approximately 1.5 kg weight reduction since starting, which was not the goal. More meaningfully, a clear attenuation of between-meal appetite noise. Not dramatic appetite suppression — more like a quieting. I feel metabolically cleaner. Whether this reflects genuine metabolic improvement or behavioral change, I cannot fully separate at this dose.
Is Microdosing Semaglutide Evidence-Based?
This is the honest part.
For normal-weight individuals using semaglutide for metabolic optimization or longevity purposes: no, there is no clinical guideline supporting this. No randomized controlled trial has evaluated this specific indication. The evidence base is early-stage and largely mechanistic.
What exists is a strong pharmacological rationale, compelling cardiovascular outcomes data from high-risk diabetic populations, and emerging pharmacogenomic evidence that identifies individuals with the most to gain from GLP-1 biology — regardless of weight.
I cannot recommend this approach to my patients. Not today. What I can say is that the question of whether microdosing semaglutide has a role in precision longevity medicine is being taken seriously by researchers, and the next five to ten years will likely produce the evidence that clarifies it.
Who Might This Be Relevant For?
Not everyone. Not most people.
The profile that warrants serious consideration — under physician supervision, with proper genetic and metabolic evaluation — includes individuals with:
- TCF7L2, PNPLA3, or FTO genetic variants indicating metabolic vulnerability
- Normal weight but documented cardiovascular risk or family history
- Favorable GIPR genotype (low GI side effect risk)
- A genuine longevity medicine framework, not weight management goals
If you are curious whether your genetic profile is relevant to GLP-1 biology, that question starts with pharmacogenomic testing — not with asking for a prescription.
Read the Full Clinical Story
This article covers the scientific framework. The complete three-layer self-experiment — my full genetic profile with all rs codes, my complete lab panel, and the detailed clinical reasoning behind my decision — is published on my Substack.
→ Read the full article: drhalilcoskun.substack.com
If the intersection of genetics, metabolic medicine, and longevity science interests you, subscribe for weekly posts.
References
- Overgaard RV et al. Cell Reports Medicine, 2021.
- Marso SP et al. NEJM, 2016 (LEADER, SUSTAIN-6).
- Nature GWAS Study. Pharmacogenomics of GLP-1 receptor agonist response in 27,885 individuals. Nature, 2026.
- Drucker DJ. Molecular Metabolism, 2022.
Prof. Dr. Halil Coşkun is a bariatric surgeon and longevity physician, founder of BariatrikLab Longevity Clinic, Istanbul.
This article is for informational purposes only. It does not constitute medical advice. Any use of GLP-1 receptor agonists should be evaluated and supervised by a qualified physician.
